BCL2 and B-cell chronic lymphocytic leukemia: Recently reported clinical results from a first-in-human phase I trial on NX-2127 involved 23 R/R CLL patients, with a median of six prior therapies (2–11), all of whom had previously undergone treatment with a covalent BTKi and/or BCL2 inhibitor venetoclax [117].